Protara Therapeutics, Inc. (TARA)

Profile

https://www.protaratx.com

Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. Its current pipeline centers on TARA-002, an investigational cell therapy being studied for non-muscle invasive bladder cancer and lymphatic malformations, and intravenous choline chloride, a phospholipid substrate replacement therapy for patients receiving parenteral nutrition. The company’s programs address areas with significant unmet medical need across oncology, rare disease, gastrointestinal, and metabolic care. Protara Therapeutics operates as a research-driven developer of specialty treatments, with its portfolio aimed at advancing targeted options for patient populations that have limited approved alternatives. Headquartered in New York, New York, the company focuses on clinical development and translational science to support its therapeutic candidates.